Experiential Training for Community Therapists
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03354975 |
|
Recruitment Status :
Completed
First Posted : November 28, 2017
Last Update Posted : January 3, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Anxiety | Behavioral: Experiential Training Behavioral: Training-As-Usual | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 28 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Health Services Research |
| Official Title: | Dissemination of Exposure-Based Treatment for Anxiety: Experiential Training for Community Therapists |
| Actual Study Start Date : | March 23, 2018 |
| Actual Primary Completion Date : | July 24, 2018 |
| Actual Study Completion Date : | November 1, 2018 |
| Arm | Intervention/treatment |
|---|---|
| Experimental: Experiential Training |
Behavioral: Experiential Training
Participants in the experiential training will be provided with information about using exposure therapy to treat patients with anxiety via lecture-style teaching. Then, they will themselves undergo a one-session phobia treatment for spiders. |
| Active Comparator: Training-as-usual |
Behavioral: Training-As-Usual
The training-as-usual condition will incorporate passive and active learning components. The first half of the training will include lecture-style teaching about using exposure therapy to treat patients with anxiety. The second half of training will incorporate active learning components (e.g., role plays) to reinforce concepts discussed in the first half of training. |
- Change from baseline Therapist Beliefs about Exposure Scale (TBES) at 3-month follow-up [ Time Frame: Pre-training; 3-month follow-up ]The Therapist Beliefs about Exposure Scale is a 21-item self-report measure that assesses therapists' negative beliefs about exposure therapy. Agreement with each item is rated on a 5-point scale ranging from 0 (disagree strongly) to 4 (agree strongly), yielding a total score ranging from 0 to 84. Higher scores indicate more negative beliefs about exposure.
- Change from baseline Exposure Therapy Clinical Use Survey (ETCUS) at 3-month follow-up [ Time Frame: Pre-training; 3-month follow-up ]The ETCUS measures therapist-reported use of nine exposure therapy procedures, such as providing the rationale for exposure therapy, creating a hierarchy, and completing in-vivo exposures.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Participants will be aged 21 and older with degrees (masters or doctorate) in a mental health field. They must be working in a community mental health clinic, currently treating at least one client with anxiety, and planning to continue providing therapy to at least one client with anxiety for the duration of the study. Participants must be interested in participating in a training workshop and able to commit to the time requirements for study completion. They must also be willing to provide an email or mailing address to complete study-related surveys. Finally, they must be able to read and speak English.
Exclusion Criteria:
- Participants cannot have previously attended a full day (8+ hours) workshop on exposure-based treatments for anxiety.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03354975
| United States, Pennsylvania | |
| Temple University | |
| Philadelphia, Pennsylvania, United States, 19122 | |
| Responsible Party: | Temple University |
| ClinicalTrials.gov Identifier: | NCT03354975 |
| Other Study ID Numbers: |
260359 F31MH112211 ( U.S. NIH Grant/Contract ) |
| First Posted: | November 28, 2017 Key Record Dates |
| Last Update Posted: | January 3, 2019 |
| Last Verified: | January 2019 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Anxiety Disorders Mental Disorders |

